<DOC>
	<DOCNO>NCT03073265</DOCNO>
	<brief_summary>The objective demonstrate performance STA® - Apixaban Calibrator &amp; STA® - Apixaban Control use combination STA® - Liquid Anti-Xa measure apixaban concentration plasma . Anti-Xa result compare LCMS ( liquid chromatography - mass spectrometry ) validation assay . For study , anti-Xa assay perform fresh sample . The result use complete result obtain previously frozen sample .</brief_summary>
	<brief_title>Apixaban Validation Study - Additional Study Fresh Samples</brief_title>
	<detailed_description>About 60 sample patient apixaban meeting inclusion/exclusion criterion include study . Two site charge sample recruitment anti-Xa testing . A third site charge LCMS testing .</detailed_description>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Age ≥ 75 year , Weight ≤ 60 kg , Haematocrit normal value determine local laboratory &lt; 40 % male &lt; 37 % female Renal impairment document ( creatinine clearance ≤ 80 mL/min per Cockcroft Gault equation ) serum creatinine ≥ 1.5 mg/dL Comedication aspirin NSAIDs ( nonsteroidal antiinflammatory drug ) Comedication antiplatelet agent Patients less 18 year old Patients anticoagulant treatment Samples collect , store , handle accordance sample collection procedure define .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DOAC</keyword>
	<keyword>apixaban</keyword>
	<keyword>IVD</keyword>
</DOC>